PortfoliosLab logo
PortfoliosLab logo
Tools
Portfolios
Screeners
Discussions
TXG vs. SBRA
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between TXG and SBRA is 0.40, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

TXG vs. SBRA

Last updated Jun 1, 2025

Compare and contrast key facts about 10x Genomics, Inc. (TXG) and Sabra Health Care REIT, Inc. (SBRA).

Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: TXG or SBRA.

Performance

TXG vs. SBRA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in 10x Genomics, Inc. (TXG) and Sabra Health Care REIT, Inc. (SBRA). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Sharpe Ratio

TXG:

-0.76

SBRA:

1.24

Sortino Ratio

TXG:

-1.00

SBRA:

1.76

Omega Ratio

TXG:

0.87

SBRA:

1.21

Calmar Ratio

TXG:

-0.60

SBRA:

1.87

Martin Ratio

TXG:

-1.47

SBRA:

4.16

Ulcer Index

TXG:

39.43%

SBRA:

7.57%

Daily Std Dev

TXG:

76.06%

SBRA:

24.82%

Max Drawdown

TXG:

-96.47%

SBRA:

-74.93%

Current Drawdown

TXG:

-95.29%

SBRA:

-6.41%

Fundamentals

Market Cap

TXG:

$1.15B

SBRA:

$4.16B

EPS

TXG:

-$1.33

SBRA:

$0.60

PS Ratio

TXG:

1.84

SBRA:

5.77

PB Ratio

TXG:

1.63

SBRA:

1.53

Total Revenue (TTM)

TXG:

$624.66M

SBRA:

$722.42M

Gross Profit (TTM)

TXG:

$429.69M

SBRA:

$517.66M

EBITDA (TTM)

TXG:

-$127.01M

SBRA:

$419.10M

Returns By Period

In the year-to-date period, TXG achieves a -33.64% return, which is significantly lower than SBRA's 4.54% return.

TXG

YTD

-33.64%

1M

17.65%

6M

-40.06%

1Y

-57.49%

3Y*

-42.90%

5Y*

-34.32%

10Y*

N/A

SBRA

YTD

4.54%

1M

0.91%

6M

-3.33%

1Y

28.64%

3Y*

16.97%

5Y*

14.36%

10Y*

4.27%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

10x Genomics, Inc.

Sabra Health Care REIT, Inc.

Go deeper with the Portfolio Analysis tool — backtest performance, assess risk, compare to benchmarks, and more

Risk-Adjusted Performance

TXG vs. SBRA — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.
TXG
The Risk-Adjusted Performance Rank of TXG is 1111
Overall Rank
The Sharpe Ratio Rank of TXG is 1111
Sharpe Ratio Rank
The Sortino Ratio Rank of TXG is 1212
Sortino Ratio Rank
The Omega Ratio Rank of TXG is 1313
Omega Ratio Rank
The Calmar Ratio Rank of TXG is 1313
Calmar Ratio Rank
The Martin Ratio Rank of TXG is 66
Martin Ratio Rank
SBRA
The Risk-Adjusted Performance Rank of SBRA is 8484
Overall Rank
The Sharpe Ratio Rank of SBRA is 8686
Sharpe Ratio Rank
The Sortino Ratio Rank of SBRA is 8181
Sortino Ratio Rank
The Omega Ratio Rank of SBRA is 7878
Omega Ratio Rank
The Calmar Ratio Rank of SBRA is 9191
Calmar Ratio Rank
The Martin Ratio Rank of SBRA is 8383
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

TXG vs. SBRA - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for 10x Genomics, Inc. (TXG) and Sabra Health Care REIT, Inc. (SBRA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current TXG Sharpe Ratio is -0.76, which is lower than the SBRA Sharpe Ratio of 1.24. The chart below compares the historical Sharpe Ratios of TXG and SBRA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Loading data...

Go to the full Sharpe Ratio tool to analyze any stock or portfolio. Customize time frames, set your own risk-free rate, and more

Dividends

TXG vs. SBRA - Dividend Comparison

TXG has not paid dividends to shareholders, while SBRA's dividend yield for the trailing twelve months is around 6.86%.

TTM20242023202220212020201920182017201620152014
TXG
10x Genomics, Inc.		0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
SBRA
Sabra Health Care REIT, Inc.		6.86%6.93%8.41%9.65%8.86%7.77%8.43%10.92%9.22%6.84%7.91%4.97%

Drawdowns

TXG vs. SBRA - Drawdown Comparison

The maximum TXG drawdown since its inception was -96.47%, which is greater than SBRA's maximum drawdown of -74.93%. Use the drawdown chart below to compare losses from any high point for TXG and SBRA.

Loading data...

Go to the full Drawdowns tool for more analysis options, including inflation-adjusted drawdowns, and more

Volatility

TXG vs. SBRA - Volatility Comparison

10x Genomics, Inc. (TXG) has a higher volatility of 19.84% compared to Sabra Health Care REIT, Inc. (SBRA) at 8.12%. This indicates that TXG's price experiences larger fluctuations and is considered to be riskier than SBRA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Loading data...

Financials

TXG vs. SBRA - Financials Comparison

This section allows you to compare key financial metrics between 10x Genomics, Inc. and Sabra Health Care REIT, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.

Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities

50.00M100.00M150.00M200.00M20212022202320242025
154.88M
183.54M
(TXG) Total Revenue
(SBRA) Total Revenue
Values in USD except per share items

TXG vs. SBRA - Profitability Comparison

The chart below illustrates the profitability comparison between 10x Genomics, Inc. and Sabra Health Care REIT, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.
Gross Margin
Operating Margin
Net Margin
Quarterly
Annual
40.0%50.0%60.0%70.0%80.0%90.0%100.0%20212022202320242025
68.1%
100.0%
(TXG) Gross Margin
(SBRA) Gross Margin
TXG - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2025, 10x Genomics, Inc. reported a gross profit of 105.45M and revenue of 154.88M. Therefore, the gross margin over that period was 68.1%.

SBRA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2025, Sabra Health Care REIT, Inc. reported a gross profit of 183.54M and revenue of 183.54M. Therefore, the gross margin over that period was 100.0%.

TXG - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2025, 10x Genomics, Inc. reported an operating income of -39.33M and revenue of 154.88M, resulting in an operating margin of -25.4%.

SBRA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2025, Sabra Health Care REIT, Inc. reported an operating income of 170.82M and revenue of 183.54M, resulting in an operating margin of 93.1%.

TXG - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2025, 10x Genomics, Inc. reported a net income of -34.36M and revenue of 154.88M, resulting in a net margin of -22.2%.

SBRA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2025, Sabra Health Care REIT, Inc. reported a net income of 40.30M and revenue of 183.54M, resulting in a net margin of 22.0%.